Targeting pathogenic monocytes

Details Targeting pathogenic monocytes Targeting pathogenic monocytes

A - Human Necessities

61

K

A61K 39/395 (2006.01) A61P 29/00 (2006.01) A61P 37/06 (2006.01) C07K 16/24 (2006.01)

Patent

CA 2737056

The invention is based on the discovery that interleukin- 1 alpha (IL-1 alpha) is expressed on the proinflammatory CD 14+CD 16+ monocyte subset. Importantly, since IL-1 alpha appears to be almost exclusively expressed on this monocyte subset and not other leukocytes, it represents an ideal marker for targeting the CD 14+CD 16+ monocyte subset. The effectiveness of an agent that depletes such pathogenic cells or modulates IL-1 alpha function on such cells type can be monitored by assessing CD 14+CD 16+ monocyte levels or functionality.

La présente invention est basée sur la découverte que linterleukine-1-alpha (IL-1-alpha) est exprimée sur le sous-ensemble de monocytes CD14+ CD16+ pro-inflammatoires. En particulier, étant donné quil apparaît quIL-1-alpha est presque exclusivement exprimée sur ce sous-ensemble de monocytes et pas sur dautres leucocytes, celle-ci représente un marqueur idéal pour cibler le sous-ensemble de monocytes CD14+ CD16+. Lefficacité dun agent qui réduit de telles cellules pathogènes ou module la fonction dIL-1-alpha sur un tel type de cellules peut être surveillée en évaluant les taux ou la fonctionnalité de monocytes CD14+ CD16+.

Affiliated with

Also associated with

Rating

Targeting pathogenic monocytes does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Targeting pathogenic monocytes, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Targeting pathogenic monocytes will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFCA-PAI-O-1928297